Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05346393 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HRS-AKI Treatment With TIPS in Patients With Cirrhosis

Study acronym: Liver-HERO
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 18, 2024 (before its estimated June 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 11 to 14
    • Eligibility criteria shortened, about 43 words
    • Collaborators revised (2)
    • Study description expanded, about 1 word
    v9
  2. Secondary endpoints: 19 to 21
    • Site details revised at 2 of 11 sites
    • Eligibility criteria shortened, about 3 words
    v8
  3. Study sites: 9 to 11
    • Eligibility criteria expanded, about 38 words
    v7
  4. Eligibility criteria expanded, about 33 words
    • Site details revised at 1 of 9 sites
    v6
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 2022 to Nov 29, 2022
    • Site details revised at 9 of 9 sites
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Start date: Oct 2022 to Dec 2022v4
  2. Start date: Jul 2022 to Oct 2022
    • Study sites: 5 to 9
    • Eligibility criteria expanded, about 61 words
    • Collaborators: 1 to 2
    v3
  3. Secondary endpoints revised (19)v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study compares the effectiveness and safety of TIPS implantation in patients with HRS-AKI (stage1, 2 and 3) and liver cirrhosis with standard therapy (drug therapy with terlipressin + albumin).
Trial Details
NCT Number NCT05346393
Lead Sponsor Jena University Hospital
Collaborators: German Research Foundation, University Hospital Halle (Saale)
Conditions
(from sponsor)		 Cirrhosis, Liver, Hepatorenal Syndrome, Acute Kidney Injury, Ascites Hepatic
Related terms Acute Kidney Injury, Ascites, Fibrosis, Hepatorenal Syndrome, Liver Cirrhosis
Enrollment 124 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov